UNSPSC 51333202: Imiquimod

This classification denotes a biological response modifier with the molecular formula C14H16N4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P1QW714R7M, chemically known as 4-amino-1-isobutyl-1h-imidazo(4,5-c)quinoline but generally known as imiquimod, which bears US NIH Compound Identifier 57469. European Medicines Agency schedules Imiquimod in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12453MIG.

UNSPSC 51333202 Imiquimod, a Commodity code, shows minimal relevant recent activity for the nominal pharmaceutical ingredient. The three recent state and local opportunities posted against this code in fact solicit naloxone and drug deactivation systems, therapeutic pharmacy initiative direct-to-manufacturer programs, and generic multi-source pharmaceuticals and OTC products—none of which align with imiquimod, an antiviral cream used topically for warts and skin lesions. The mismatch between the code's name and the actual procurement scope suggests tagging inconsistency in the source systems rather than active market demand under this specific commodity code.

The geographic spread of recent activity covers Florida (Seminole County), Texas (Health and Human Services Commission), and Minnesota (MMCAP cooperative purchasing serving multiple states including Oregon), but the opportunities themselves—a naloxone and drug deactivation system IFB due July 26, 2023; a Texas HHS RFI on direct-to-manufacturer pharmacy programs posted April 3, 2026; and an MMCAP RFP for generic pharmaceuticals and OTC products due March 26, 2026—target broad pharmaceutical procurement categories rather than the imiquimod commodity specifically. State and local procurement activity tagged to this code does not reflect meaningful demand for imiquimod as a line item.